184 related articles for article (PubMed ID: 34434196)
1. Insights Into the Structure-Function Relationships of Dimeric C3d Fragments.
Wahid AA; Dunphy RW; Macpherson A; Gibson BG; Kulik L; Whale K; Back C; Hallam TM; Alkhawaja B; Martin RL; Meschede I; Laabei M; Lawson ADG; Holers VM; Watts AG; Crennell SJ; Harris CL; Marchbank KJ; van den Elsen JMH
Front Immunol; 2021; 12():714055. PubMed ID: 34434196
[TBL] [Abstract][Full Text] [Related]
2. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism.
Rodriguez E; Nan R; Li K; Gor J; Perkins SJ
J Biol Chem; 2015 Jan; 290(4):2334-50. PubMed ID: 25488663
[TBL] [Abstract][Full Text] [Related]
3. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
Clemenza L; Isenman DE
J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
[TBL] [Abstract][Full Text] [Related]
4. A structural basis for Staphylococcal complement subversion: X-ray structure of the complement-binding domain of Staphylococcus aureus protein Sbi in complex with ligand C3d.
Clark EA; Crennell S; Upadhyay A; Zozulya AV; Mackay JD; Svergun DI; Bagby S; van den Elsen JM
Mol Immunol; 2011 Jan; 48(4):452-62. PubMed ID: 21055811
[TBL] [Abstract][Full Text] [Related]
5. Structure at 1.44 A resolution of an N-terminally truncated form of the rat serum complement C3d fragment.
Zanotti G; Bassetto A; Battistutta R; Folli C; Arcidiaco P; Stoppini M; Berni R
Biochim Biophys Acta; 2000 May; 1478(2):232-8. PubMed ID: 10825534
[TBL] [Abstract][Full Text] [Related]
6. Interaction of fibronectin with complement component C3.
Hautanen A; Keski-Oja J
Scand J Immunol; 1983 Mar; 17(3):225-30. PubMed ID: 6402811
[TBL] [Abstract][Full Text] [Related]
7. Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.
Meuth JL; Morgan EL; DiSipio RG; Hugli TE
J Immunol; 1983 Jun; 130(6):2605-11. PubMed ID: 6602172
[TBL] [Abstract][Full Text] [Related]
8. Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d.
Li K; Gor J; Holers VM; Storek MJ; Perkins SJ
J Mol Biol; 2012 May; 418(3-4):248-63. PubMed ID: 22387467
[TBL] [Abstract][Full Text] [Related]
9. Multimeric interactions between complement factor H and its C3d ligand provide new insight on complement regulation.
Okemefuna AI; Li K; Nan R; Ormsby RJ; Sadlon T; Gordon DL; Perkins SJ
J Mol Biol; 2009 Aug; 391(1):119-35. PubMed ID: 19505474
[TBL] [Abstract][Full Text] [Related]
10. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
[TBL] [Abstract][Full Text] [Related]
11. Regulation of human cytotoxic responses by complement: C3, C3b and C3d preparations enhance human allogeneic cytotoxic responses.
Tsokos GC; Inghirami G; Lambris JD
J Immunopharmacol; 1986; 8(4):529-41. PubMed ID: 2949021
[TBL] [Abstract][Full Text] [Related]
12. The covalent interaction of C3 with IgG immune complexes.
Vivanco F; Muñoz E; Vidarte L; Pastor C
Mol Immunol; 1999; 36(13-14):843-52. PubMed ID: 10698338
[TBL] [Abstract][Full Text] [Related]
13. Interaction of soluble C3 fragments with guinea pig lymphocytes. Comparison of effects of C3a, C3b, C3c, and C3d on lymphokine production and lymphocyte proliferation.
Koopman WJ; Sandberg AL; Wahl SM; Mergenhagen SE
J Immunol; 1976 Jul; 117(1):331-6. PubMed ID: 932430
[TBL] [Abstract][Full Text] [Related]
14. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
15. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study.
Gilbert HE; Eaton JT; Hannan JP; Holers VM; Perkins SJ
J Mol Biol; 2005 Feb; 346(3):859-73. PubMed ID: 15713468
[TBL] [Abstract][Full Text] [Related]
16. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity.
Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Jun; 153(6):1592-603. PubMed ID: 7252421
[TBL] [Abstract][Full Text] [Related]
17. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
[TBL] [Abstract][Full Text] [Related]
18. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2.
Nagar B; Jones RG; Diefenbach RJ; Isenman DE; Rini JM
Science; 1998 May; 280(5367):1277-81. PubMed ID: 9596584
[TBL] [Abstract][Full Text] [Related]
19. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
Shaw CD; Storek MJ; Young KA; Kovacs JM; Thurman JM; Holers VM; Hannan JP
J Mol Biol; 2010 Dec; 404(4):697-710. PubMed ID: 20951140
[TBL] [Abstract][Full Text] [Related]
20. A complement C3 fragment equivalent to mammalian C3d from the common carp (Cyprinus carpio): generation in serum after activation of the alternative pathway and detection of its receptor on the lymphocyte surface.
Nakao M; Miura C; Itoh S; Nakahara M; Okumura K; Mutsuro J; Yano T
Fish Shellfish Immunol; 2004 Feb; 16(2):139-49. PubMed ID: 15123318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
